THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH

C5LHMPRJ9J19

3D9G5

2026-02-24

2025-02-26

2003-03-15

3D9G5

Active

Non-Manufacturer

2025-02-26

2030-02-26

2026-02-24

DIANE M. MARBURY

75N96023P00215

View Award on USAspending website

AWARD

PURCHASE ORDER

21361.00

21361.00

21361.00

Department of Health and Human Services

2023-08-30

EXAMINING VITAMIN D AND REPRODUCTIVE FUNCTION USING MENSTRUAL EFFLUENT

541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

B504: SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL

75N98022C00019

View Award on USAspending website

AWARD

DEFINITIVE CONTRACT

1964943.97

1964943.97

0.00

Department of Health and Human Services

2022-09-21

RECONSTRUCTING VAGAL ANATOMY OP2

541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

R499: SUPPORT- PROFESSIONAL: OTHER

75D30120C07974

View Award on USAspending website

AWARD

DEFINITIVE CONTRACT

0.00

0.00

0.00

Department of Health and Human Services

2020-04-28

STUDY OF CANCER INCIDENCE AMONG PACE UNIVERSITY EMPLOYEES

541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

AN41: HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH

2025-05-08

View on USAspending

Department of Defense

STUDYING URINE MACROPHAGES IN LUPUS NEPHRITIS TO SHED LIGHT ON KIDNEY DISEASE PROCESSES

999972.00

0.00

0.00

2025-04-29

View on USAspending

Department of Health and Human Services

2/5-BIOMARKERS TO ENHANCE EARLY SCHIZOPHRENIA TREATMENT (BEEST) - PROJECT SUMMARY THE ONSET OF A FIRST EPISODE OF PSYCHOSIS (FEP) IN LATE ADOLESCENCE OR EARLY ADULTHOOD OFTEN LEADS TO LIFELONG DISABILITY. TIMING AND PRECISION OF TREATMENT ARE OF THE ESSENCE DURING THIS CRITICAL DEVELOPMENTAL PERIOD. UNFORTUNATELY, FEP PATIENTS WHO DO NOT RESPOND TO A CONVENTIONAL FIRST-LINE ANTIPSYCHOTIC (FL-AP) ARE OFTEN DELAYED IN TRANSITIONING TO CLOZAPINE (CLZ) - OR NEVER SWITCH AT ALL - DESPITE THE CLEAR SUPERIORITY OF CLZ TO FL- APS IN TREATMENT RESISTANT INDIVIDUALS. HOWEVER, CLZ TREATMENT INVOLVES RISKS OF SEVERE SIDE EFFECTS, INCLUDING AGRANULOCYTOSIS AND WEIGHT GAIN. CURRENTLY, CLINICIANS AND PATIENTS CURRENTLY HAVE NO OBJECTIVE, CLINICALLY VALIDATED TOOLS TO GUIDE THIS COMPLEX DECISION MAKING IN FEP. OUR COLLABORATIVE GROUP HAS RECENTLY PUBLISHED WORK SHOWING THAT A FUNCTIONAL BRAIN SCAN CAN HELP PREDICT WHICH FEP PATIENTS MIGHT NOT RESPOND TO FL-APS, SUCH AS ARIPIPRAZOLE AND RISPERIDONE. FURTHER, WE HAVE SHOWN THAT A SIMPLE GENETICS TEST CAN HELP PREDICT WHO IS LESS LIKELY TO GAIN SIGNIFICANT WEIGHT, AND, SIMILARLY, WHO IS LESS LIKELY TO DEVELOP AGRANULOCYTOSIS. WE PROPOSE TO CONDUCT A MULTI-CENTER, HARMONIZED, RANDOMIZED CLINICAL TRIAL WITH THE GOAL OF TESTING WHETHER THE USE OF BIOMARKERS CAN LEAD TO BETTER OUTCOMES FOR FEP PATIENTS. THE GOAL OF THE PROPOSED STUDY IS TO DEVELOP A CLOZAPINE DECISION SUPPORT TOOL BASED ON THESE BIOMARKERS. FIRST, WE WILL CHARACTERIZE 410 PEOPLE WITH AN FEP USING THREE SPECIFIC BIOMARKERS: A RESTING STATE FMRI SCAN FROM WHICH WE WILL DERIVE THE STRIATAL CONNECTIVITY INDEX (SCI) AND TWO GENETICS TESTS (ONE FOR WEIGHT GAIN AND THE OTHER FOR AGRANULOCYTOSIS). THOSE PATIENTS WHO ARE PREDICTED TO NOT RESPOND TO FL-APS, AND WHO ALSO HAVE LOW RISK OF WEIGHT GAIN AND AGRANULOCYTOSIS (APPROXIMATE N=180), WILL BE RANDOMIZED IN A TRIPLE-BLIND CONTROLLED STUDY TO EITHER CLOZAPINE OR AN FL-AP (EITHER ARIPIPRAZOLE OR RISPERIDONE) FOR 12 WEEKS OF TREATMENT. OUR MAIN OUTCOMES RELATE TO CLINICAL RESPONSE, INCLUDING POSITIVE SYMPTOMS, SUICIDAL THINKING, AND DAYS OF HOSPITALIZATION. WE WILL ALSO PERFORM AN MRI AT STUDY END TO DETERMINE WHETHER FUNCTIONAL PATTERNS IN THE BRAIN DISTINGUISH CLZ RESPONDERS FROM NON-RESPONDERS (TARGET ENGAGEMENT). CRITICALLY, WE ARE PARTNERING WITH PEOPLE WITH LIVED EXPERIENCE OF PSYCHOSIS AND FAMILY MEMBERS TO HELP GUIDE US DURING THIS TRIAL, AND TO INFORM THE STUDY DESIGN AND OUTCOMES; INFORMATION AND CHOICE ARE AMONGST THE STRONGEST ELEMENTS OF A SUCCESSFUL THERAPEUTIC RELATIONSHIP. OVERALL, OUR STUDY WILL EVALUATE THE EFFICACY OF WHETHER USING THREE BIOMARKERS AT THE BEGINNING OF A FIRST PSYCHOTIC EPISODE CAN LEAD TO BETTER PATIENT OUTCOMES FOR PATIENTS AT RISK FOR POOR RESPONSE, BY RAPIDLY INTRODUCING CLZ RATHER THAN WAITING FOR MULTIPLE FAILURES OF FL-APS. OUR KEY DELIVERABLE WOULD BE A CLOZAPINE DECISION SUPPORT TOOL, CONSISTING OF THE THREE BIOMARKERS COMBINED WITH OUR CLZ DOSING STRATEGY FOR FEP. SUCH A TOOL WOULD BE A NECESSARY STEP IN THE DEVELOPMENT OF PRECISION PSYCHIATRY; IF THIS EFFICACY TRIAL IS SUCCESSFUL, A FUTURE STUDY WOULD THEN UTILIZE IMPLEMENTATION SCIENCE TO OPTIMIZE STRATEGIES FOR DISSEMINATION OF THE DECISION SUPPORT TOOL.

608943.00

0.00

0.00

2025-04-24

View on USAspending

Department of Defense

IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF METASTASIS-DRIVING TUMOR CELL SUBPOPULATIONS IN LOCALIZED STAGE III CLEAR CELL RENAL CELL CARCINOMA. 1. THE PURPOSE OF THIS MODIFICATION IS TO CHANGE THE PRINCIPAL INVESTIGATOR FROM ANNETTE LEE TO ANDREW J. SHIH. 2. UPDATES DIVISION I ITEM: B.4

1339689.00

0.00

0.00

2025-05-17

View on USAspending

Department of Health and Human Services

LEVERAGING HEATH INFORMATION TECHNOLOGY TO IMPROVE POST-DISCHARGE MANAGEMENT FOR PATIENTS WITH HEART FAILURE - PROJECT SUMMARY MY LONG-TERM CAREER GOAL IS TO BECOME A CLINICIAN INVESTIGATOR, WHO USES HEALTH INFORMATION TECHNOLOGY (IT) TO IMPROVE CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH SOCIAL NEEDS. THE RESEARCH GOAL OF THIS APPLICATION IS TO USE HEALTH IT TO REDUCE PREVENTABLE READMISSIONS FOR HEART FAILURE (HF) AMONG PATIENTS WITH LOW HEALTH LITERACY WITH THE INCORPORATION OF BEHAVIORAL SCIENCE AND USABILITY TESTING. SOCIAL DETERMINANTS OF HEALTH (SDH) ACCOUNT FOR 80% OF HEALTH OUTCOMES, AND SOCIAL NEEDS ARE ASSOCIATED WITH POOR HEALTH OUTCOMES, INCLUDING 30-DAY READMISSIONS. ADDRESSING INDIVIDUALS’ SOCIAL NEEDS HAS BEEN ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES, BUT MAY TAKE A PROLONGED TIME TO EFFECTIVELY REDUCE 30-DAY READMISSIONS. HEALTH LITERACY, WHICH MEASURES A PATIENT’S ABILITY TO FIND, UNDERSTAND, AND USE INFORMATION AND SERVICES TO INFORM HEALTH-RELATED DECISIONS AND ACTIONS FOR THEMSELVES AND OTHERS, IS ASSOCIATED WITH PATIENTS’ HEALTH OUTCOMES. LOW HEALTH LITERACY IS COMMON AMONG PATIENTS WITH HF, AND LEADS TO POOR MANAGEMENT OF HF. EXTANT INTERVENTIONS, SUCH AS PATIENT NAVIGATORS AND HANDOUTS, HAVE BEEN UTILIZED SUCCESSFULLY TO IMPROVE MEDICAL CARE FOR PATIENTS WITH LOW HEALTH LITERACY, BUT THEY ARE EPISODIC AND RESOURCE-INTENSIVE. THE USE OF HEALTH IT TOOLS, SUCH AS A PERSONALIZED, AUTOMATED TEXT-MESSAGE-BASED APPLICATION, CAN BE UTILIZED FOR POST-HOSPITALIZATION CARE. OUR PRELIMINARY STUDY INDICATES THAT PATIENTS WITH HF WHO USE THIS APPLICATION HAD REDUCED 30-DAY READMISSIONS, COMPARED TO PATIENTS WITH HF WHO DID NOT USE THE APPLICATION. HOWEVER, THE NUMBER OF PATIENTS WITH HF USING THE APPLICATION HAS BEEN LIMITED, DUE TO LOW UPTAKE AND HIGH ATTRITION RATE. THE OVERALL OBJECTIVE OF THE PROPOSED RESEARCH PROJECT IS TO INCORPORATE NUDGES, AND ADDRESS BARRIERS TO IMPROVE PATIENTS’ USE OF THE APPLICATION, AND CONDUCT A PILOT RANDOMIZED CONTROLLED TRIAL (RCT) TO EVALUATE THE APPLICATION’S USE IN REDUCING 30-DAY READMISSIONS. WE WILL CONDUCT QUALITATIVE WORK TO GAIN INSIGHTS INTO HOW TO ADAPT AN EXTANT TEXT MESSAGING INTERVENTION TO IMPROVE ITS USE AMONG PATIENTS WITH LOW HEALTH LITERACY (AIM 1), CONDUCT USABILITY TESTING AND ITERATIVE REVISION OF THE APPLICATION (AIM 2), AND CONDUCT A PILOT RCT TO EVALUATE THE ACCEPTABILITY, FEASIBILITY, AND PRELIMINARY EFFICACY OF USING BEHAVIORAL INTERVENTIONS TO INCREASE THE APPLICATION USE FOR PATIENTS WITH HF POST-DISCHARGE (AIM 3). THE TRAINING FROM THIS MENTORED CAREER DEVELOPMENT AWARD WILL PROVIDE SKILLS IN FOUR DOMAINS: 1) BEHAVIORAL SCIENCE; 2) IMPLEMENTATION SCIENCE; 3) HEALTH LITERACY; AND 4) RCT DESIGN AND CONDUCT. THE PROPOSED RESEARCH ACTIVITIES, AND THE TRAINING AND MENTORING PLANS WILL PROVIDE THE FOUNDATION FOR MY CAREER AS AN INDEPENDENT CLINICIAN INVESTIGATOR.

573022.00

0.00

0.00

2025-04-04

View on USAspending

Department of Health and Human Services

KIDS: NOCTURNAL INVESTIGATION INTO GLOMERULAR DISEASE, HYPERTENSION, AND TRANSCRIPTOMICS (KNIGHT) - PROJECT SUMMARY/ABSTRACT CHILDREN WITH PROTEINURIC GLOMERULOPATHIES ARE AT CONSIDERABLE RISK FOR CARDIOVASCULAR DISEASE. IN ADDITION TO THE HIGH PREVALENCE OF TRADITIONAL CARDIOVASCULAR DISEASE RISK FACTORS IN THIS POPULATION, MORE THAN HALF OF CHILDREN WITH PROTEINURIC GLOMERULOPATHIES EXPERIENCE NOCTURNAL BLOOD PRESSURE DYSREGULATION, DEFINED BY NOCTURNAL HYPERTENSION OR A REDUCED DECLINE IN NOCTURNAL BLOOD PRESSURE (NON-DIPPING PATTERN). NOCTURNAL BLOOD PRESSURE DYSREGULATION IS INDEPENDENTLY ASSOCIATED WITH POOR CARDIOVASCULAR DISEASE OUTCOMES IN ADULTS. IN THIS CONTEXT, THE OBJECTIVE OF THIS PROPOSAL IS TO UNDERSTAND THE CARDIOVASCULAR DISEASE RISKS, CLINICAL PREDICTORS AND MOLECULAR MARKERS ASSOCIATED WITH NOCTURNAL BLOOD PRESSURE DYSREGULATION IN CHILDREN WITH PROTEINURIC GLOMERULOPATHIES. THE CENTRAL HYPOTHESIS IS THAT NOCTURNAL BLOOD PRESSURE DYSREGULATION IS INDEPENDENTLY ASSOCIATED WITH PROGRESSION OF CARDIOVASCULAR TARGET ORGAN DAMAGE OVER TIME IN CHILDREN WITH PROTEINURIC GLOMERULOPATHIES. IT IS FURTHER HYPOTHESIZED THAT CLINICAL AND MOLECULAR MARKERS WILL BE ASSOCIATED WITH THE NOCTURNAL BLOOD PRESSURE DYSREGULATION PHENOTYPE. THE SPECIFIC AIMS OF THIS PROPOSAL ARE: (AIM 1) TO DETERMINE HOW NOCTURNAL BLOOD PRESSURE DYSREGULATION ASSOCIATES WITH TARGET ORGAN DAMAGE OVER TIME IN CHILDREN WITH PROTEINURIC GLOMERULOPATHIES; (AIM 2) TO IDENTIFY SLEEP- AND CIRCADIAN-RELATED PREDICTORS OF NOCTURNAL BLOOD PRESSURE DYSREGULATION IN CHILDREN WITH PROTEINURIC GLOMERULOPATHIES; (AIM 3) TO INVESTIGATE MOLECULAR PATHWAYS, NETWORKS AND METABOLIC ALTERATIONS ASSOCIATED WITH NOCTURNAL BLOOD PRESSURE DYSREGULATION IN CHILDREN WITH PROTEINURIC GLOMERULOPATHIES USING MULTI-OMIC DATA INTEGRATION . THE PROPOSED STUDY WILL INVESTIGATE NOCTURNAL BLOOD PRESSURE DYSREGULATION IN A MULTI-CENTER, LONGITUDINAL OBSERVATIONAL STUDY OF 120 CHILDREN WITH PROTEINURIC GLOMERULOPATHIES ENROLLED FROM THE NEPHROTIC SYNDROME STUDY NETWORK (NEPTUNE) AND CURE GLOMERULONEPHROPATHY NETWORK (CUREGN). CARDIOVASCULAR MEASURES WILL BE FOLLOWED FOR THREE YEARS TO DETERMINE HOW THE NOCTURNAL BP DYSREGULATION PHENOTYPE ASSOCIATES WITH PROGRESSION OF CARDIOVASCULAR TARGET ORGAN DAMAGE. PREDICTIVE MODELS WILL THEN BE DEVELOPED USING MACHINE LEARNING METHODS TO IDENTIFY THE CLINICAL PREDICTORS OF NOCTURNAL BLOOD PRESSURE DYSREGULATION, WITH A PARTICULAR EMPHASIS ON SLEEP- AND CIRCADIAN-RELATED PREDICTORS. FURTHER, A PRECISION MEDICINE APPROACH WILL BE EMPLOYED TO DEFINE MOLECULAR MARKERS OF NOCTURNAL BLOOD PRESSURE DYSREGULATION USING MULTI-OMIC DATA (GENOMICS, TRANSCRIPTOMICS, PROTEOMICS, METABOLOMICS) INTEGRATION. TO THIS END, IDENTIFYING THE HEALTH RISKS, CLINICAL PREDICTORS AND MOLECULAR MARKERS ASSOCIATED WITH NOCTURNAL BLOOD PRESSURE DYSREGULATION AMONG CHILDREN WITH PROTEINURIC GLOMERULOPATHIES USING INNOVATIVE BIOINFORMATICS APPROACHES TO ANALYZE EXISTING AND NOVEL DATA WILL FILL A SIGNIFICANT KNOWLEDGE GAP FOR A POPULATION OF CHILDREN AT GREAT CARDIOVASCULAR RISK. THIS STUDY WILL ULTIMATELY GUIDE PREVENTION AND TREATMENT TO MEANINGFULLY IMPROVE CARDIOVASCULAR DISEASE OUTCOMES IN THESE CHILDREN WITH PROTEINURIC GLOMERULOPATHIES.

2143143.00

0.00

0.00